Potent FFA2 antagonist (IC50 = 9 nM). Exhibits selectivity for FFA2 over FFA3. Inhibits acetate-induced human neutrophil migration in plasma or buffer. Also inhibits FFA2-induced expression of CD11b activation-specific epitope (AE) in human whole blood. Orally bioavailable.
|Storage||Store at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
|1eq. NaOH||9.7||20mM with gentle warming|
Preparing Stock Solutions
The following data is based on the product molecular weight 485. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.06 mL||10.31 mL||20.62 mL|
|5 mM||0.41 mL||2.06 mL||4.12 mL|
|10 mM||0.21 mL||1.03 mL||2.06 mL|
|50 mM||0.04 mL||0.21 mL||0.41 mL|
The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.
References are publications that support the products' biological activity.
Pizzonero et al (2014) Discovery and optimization of an azetidine chemical series as a free fatty acid receptor 2 (FFA2) antagonist: from hit to clinic. J.Med.Chem. 57 10044 PMID: 25380412
If you know of a relevant reference for GLPG 0974, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: GLPG 0974, supplier, GLPG0974, free, fatty, acid, receptors, FFA2, antagonists, antagonism, potent, Free, Fatty, Acid, Receptors, Free, Fatty, Acid, Receptors, Tocris Bioscience
Citations for GLPG 0974
Citations are publications that use Tocris products.
Currently there are no citations for GLPG 0974. Do you know of a great paper that uses GLPG 0974 from Tocris? If so please let us know.